Preclinical studies have shown that increased expression of RB and cyclin D1 and deletion of p16 are associated with the effects of palbociclib on breast cancer, lymphoma, sarcoma, and other tumors including lung cancer (43). This evidence concerns the gene CCND1 and sarcoma.